The strong sequential revenue growth and expanding commercial footprint are positive signals for a pre-profitability commercial-stage medtech. The reiterated $3-4M full-year guidance implies accelerating growth through 2026. However, the widening net loss and cash burn rate (~$3.5M/quarter) mean the $12.4M cash runway is about 3-4 quarters without additional financing. Watch for continued quarterly revenue acceleration and TIGeR-PaC enrollment completion in June as key catalysts.
Price Chart
Executive Summary
RenovoRx reported Q1 2026 revenue of $563,000, a 136% sequential increase from Q4 2025 and exceeding 50% of full-year 2025 revenue, driven by expansion to 16 active commercial cancer centers. The net loss widened to $3.5M from $2.4M a year ago, with SG&A costs rising as the company built commercial infrastructure. The company reiterated full-year 2026 revenue guidance of $3-4 million and ended the quarter with $12.4M in cash, sufficient to fund operations into at least H2 2027.
Key Financial Metrics
Key Facts
- Q1 2026 revenue of $563,000, up 136% QoQ from Q4 2025 and 186% YoY from $197,000
- Active commercial cancer centers grew to 16 as of May 6, 2026, from 8 at end of 2025
- Net loss of $3.5M vs $2.4M in Q1 2025, driven by SG&A increase to $2.7M from $1.6M
- Cash and equivalents of $12.4M as of March 31, 2026, after $10M private placement in March
- Phase III TIGeR-PaC trial enrollment expected to close in June 2026, with final data anticipated in mid-to-late 2027
- Full-year 2026 revenue guidance reiterated at $3-4 million
Financial Impact
Revenue of $563K vs consensus $463K, a 21.6% beat. Net loss of $3.5M was wider than the $2.4M loss in Q1 2025, but in line with the company's investment phase.
Risk Factors
- Cash runway of ~3-4 quarters at current burn rate may require additional financing before H2 2027
- TIGeR-PaC trial results are binary and not expected until 2027; interim data is deferred
- Commercial adoption is still early — 16 active centers vs 36 target by year-end 2026
- S-3 shelf filed in April 2026 allows resale of up to 15.96M shares, creating potential overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-224080 |
| Document: 0001193125-26-224080-index.html | 0001193125-26-224080 |
| Document: 0001193125-26-224080.txt | 0001193125-26-224080 |
| 8-K Data (Synthetic) | 0001193125-26-224080 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | Press Release | $1.27 | awaiting T+60 | — | $1.41 (+11.02%) |
Jul 29, 2026 12w ago | Press Release | $0.8981 $1.27 | ▲ +41.41% | ▲ +36.68% | $1.41 (+57.00%) |
Jul 2, 2026 16w ago | 8-K | $0.9201 $1.68 | ▼ −82.59% | ▼ −79.58% | $1.41 (−53.24%) |
May 26, 2026 22w ago | Press Release | $0.9160 $1.32 | ▲ +43.56% | ▲ +40.83% | $1.41 (+53.93%) |
May 19, 2026 23w ago | Press Release | $0.8060 $1.26 | ▲ +56.33% | ▲ +50.04% | $1.41 (+74.94%) |
May 15, 2026 23w ago | 10-K/A | $0.7830 $1.12 | ▲ +43.04% | ▲ +38.19% | $1.41 (+80.08%) |
May 14, 2026 23w ago | 8-K | $0.8200 $1.15 | ▲ +40.24% | ▲ +35.73% | $1.41 (+71.95%) |
Apr 29, 2026 25w ago | Press Release | $0.8310 $0.8653 | ▲ +4.13% | ▲ +0.02% | $1.41 (+69.68%) |
Apr 28, 2026 26w ago | EFFECT | $0.8400 $0.8545 | ▲ +1.73% | ▼ −2.26% | $1.41 (+67.86%) |
Apr 16, 2026 27w ago | S-3 | $1.00 $0.8500 | ▼ −15.00% | ▼ −21.14% | $1.41 (+41.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers